May 17, 2018 / 11:37 PM / 6 days ago

BRIEF-Novartis, Amgen Announce FDA Approval Of Aimovig Treatment For Migraine Prevention

May 17 (Reuters) - Novartis Ag:

* NOVARTIS AND AMGEN ANNOUNCE FDA APPROVAL OF AIMOVIG™ (ERENUMAB-AOOE), A NOVEL TREATMENT DEVELOPED SPECIFICALLY FOR MIGRAINE PREVENTION

* EMA MARKETING AUTHORIZATION APPLICATION FOR AIMOVIG IS UNDER REVIEW. NOVARTIS EXPECTS APPROVAL IN EU IN COMING MONTHS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below